Topographic genotyping of colorectal carcinoma: From a molecular carcinogenesis model to clinical relevance

Annals of Surgical Oncology

Volumn 4, Issue 3, 1997, Pages 269-278

  Pricolo, Victor E ^a,c   Finkelstein, Sydney D ^b   Bland, Kirby I ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Colorectal carcinoma; Oncogene; p53; ras; Tumor suppressor gene

Indexed keywords

BIOLOGICAL MODEL; CARCINOMA; COLORECTAL TUMOR; GENETICS; GENOTYPE; HUMAN; ONCOGENE RAS; REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA; COLORECTAL NEOPLASMS; GENES, P53; GENES, RAS; GENOTYPE; HUMANS; MODELS, GENETIC;

EID: 0031111435     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02306621     Document Type: Review

References (89)

1. Weinberg R. Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-21.
2. Knudson A. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21.
3. Levine A. The tumor suppressor genes. Annu Rev Biochem 1993;62:623-51.
4. Koorey D, McCaughan G. Tumour suppressor genes and colorectal neoplasia. J Gastroenterol Hepatol 1993;8:174-84.
5. Yaremko M, Wasylyshyn M, Westbrook C, Michelassi F. Oncogenes, suppressor genes, and allele losses in colon cancer. Adv Surg 1993;26:323-32.
6. Fearon E. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med 1994;39:123-47.
7. Thomas G. Advances in the genetics and molecular biology of colorectal tumors. Curr Opin Oncol 1994;6:406-12.
8. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525-32.
9. Fearon D, Cho K, Nigro J, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56.
10. Fearon E, Jones P. Progressing toward a molecular description of colorectal cancer development. FASEB J 1992;6:2783.
11. Williams A, Browne S, Manning A, Hague A, van der Stappen JW, Parsheva C. Biological consequences of the genetic changes which occur during human colorectal carcinogenesis. Semin Cancer Biol 1993;4:153-9.
12. Boland C. The biology of colorectal cancer. Implications for pretreatment and follow-up management. Cancer 1993; 71:4180-6.
13. Muleris M, Laurent-Puig P, Salmon R, Thomas G, Dutrillaux B. Chromosome 12 alterations and c-Ki-ras mutations in colorectal tumors. Cancer Genet Cytogenet 1993;69:161-2.
14. Blondal J, Benchimol S. The role of p53 in tumor progression. Semin Cancer Biol 1994;5:177-86.
15. Rao A, Kagan A, Chan P, Gilbert H, Nussbaum H, Hintz B. Patterns of recurrence following curative resection alone for adenocarcinoma of the rectum and sigmoid colon. Cancer 1981;48:1492-5.
16. Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983;52:1317-29.
17. Pipas J, Pogue-Geile K, Finley G, Cartwright CA, Meiesler AI. Gene structure and expression in colorectal cancer. Adv Exp Med Biol 1993;330:67-75.
18. Chapuis P, Dent O, Fisher R, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985;72:698-702.
19. Shepherd N, Saraga E, Love S, Jass J. Prognostic factors in colonie cancer. Histopathology 1989;14:613-20.
20. Giaretti W, Danova M, Geido E, et al. Flow cytometric DNA index in the prognosis of colorectal cancer. Cancer 1991; 67:1921-7.
21. Bauer KD, Bagwell CB, Giaretti W, et al. Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry 1993;14:86-91.
22. Hackford A. Biochemical markers for colorectal cancer. Diagnostic and therapeutic implications. Surg Clin North Am 1993;73:85-102.
23. Niv Y. Mucin and colorectal cancer metastasis. Am J Gastroenterol 1994;89:665-9.
24. Bottger T, Potratz D, Stockle M, Wellek S, Klupp J, Junginger T. Prognostic value of DNA analysis in colorectal carcinoma. Cancer 1993;72:3579-87.
25. Minsky B, Mies C, Rich T, Recht A. Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer. Int J Radiat Oncol Biol Phys 1989;17:311-8.
26. Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specific metastasis. Cancer Metast Rev 1993; 12:345-61.
27. Kane K. The genetics of colorectal carcinoma. Ann Clin Lab Sci 1994;24:287-93.
28. Wallich R, Bulbuc N, Hammerling G, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985;315:301-5.
29. Folkman J, Klagsburn M. Angiogenetic factors. Science 1989;339:58-60.
30. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991;51:6372-80.
31. Murakami R, Tsukuma H, Kanamori S, et al. Natural history of colorectal polyps and the effect of polypectomy on occurrence of subsequent cancer. Int J Cancer 1990;46:159-64.
32. Hamilton S. The adenoma-adenocarcinoma sequence in the large bowel: variations on a theme. J Cell Biochem 1992;16G:41-6.
33. Scott R, Muller H. Familial and genetic aspects of colorectal carcinogenesis. Eur J Cancer 1993;29A:2163-7.
34. Tudek B, Bird R, Bruce W. Foci of aberrant crypts in the colon of mice and rats exposed to carcinogens associated with foods. Cancer Res 1989;49:1236-40.
35. Kinzler K, Nilbert M, Su L, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
36. Nakamura Y. The role of the adenomatous polyposis coli APC gene in human cancers. Adv Cancer Res 1993;62:65-87.
37. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
38. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425-34.
39. Lynch HT, Schuelke GS, Kimberling WJ, et al. Hereditary non-polyposis colorectal cancer (Lynch syndromes I and II) biomarker studies. Cancer 1985;56:939-51.
40. Lynch H, Smyrk T, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993;104:1535-49.
41. Lynch H, Lynch J. The Lynch syndromes [Review]. Curr Opin Oncol 1993;5:687-96.
42. Fishel R, Lescoe K, Rao M, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38.
43. Leach F, Nicolaides N, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
44. Bronner C, Baker S, Morrison P, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994; 368:258-61.
45. Papadopoulos N, Nicolaides N, Wei Y, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263:1625-9.
46. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
47. Bos J. ras oncogene in human cancer: a review. Cancer Res 1989;49:4682-9.
48. Bos J, Fearon E, Hamilton S, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
49. Losi L, Benhattar J, Costa J. Stability of k-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992;28:1115-20.
50. Vogelstein B, Fearon E, Kern S, et al. Allelotype of colorectal carcinomas. Science 1989;244:207-11.
51. Bell S, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
52. Alitalo K, Schwab M, Linn C, Varmus HE, Bishop JM. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci USA 1983;80:1707-11.
53. D'Emilia J, Bulovas K, D'Ercole D, Wolf B, Stelle GJ, Summerhayes IC. Expression of the c-erbB-2 gene product (P-185) at different stages of neoplastic progression in the colon. Oncogene 1989;4:1233-9.
54. Melhem M, Meisler A, Finley G, et al. Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors. Cancer Res 1992;52:5853-64.
55. Heider K-H, Dammrich J, Skroch-Angel P, et al. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993;53:4197-203.
56. Cooper DL, Dougherty GJ. To metastasize or not? A question of CD44 splice site selection. Nature Med News Views (in press).
57. Kim H, Yang X-L, Rosada C, Hamilton SR, August JT. CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation. Arch Biochem Biophys 1994;310:504-7.
58. Winawer S, Zauber A, O'Brien M, et al. The National Polyp Study: design, methods and characteristics of patients with newly diagnosed polyps. Cancer 1992;70:1236-45.
59. Fearon EF, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
60. Hedrick L, Cho K, Fearon E, et al. The role of the DCC gene in colorectal tumorigenesis. Cancer Res Clin 1992;1:90.
61. Peltomaki P, Sistonen P, Mecklin J, et al. Evidence supporting exclusion of the DCC gene and a portion of chromosome 18q as the locus for susceptibility to hereditary nonpolyposis colorectal carcinomas in five kindreds. Cancer Res 1991; 51:4135-40.
62. Harris C, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
63. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
64. Meling G, Lothe R, Borresen A, et al. The TP53 tumour suppressor gene in colorectal carcinomas - genetic alterations on chromosome 17. Br J Cancer 1993;67:88-92.
65. Prives C, Manfredi J. The p53 tumour suppressor protein: meeting review. Genes Dev 1993;7:529-34.
66. Baker S, Markowitz S, Fearon E, Wilson J, Vogelstein B. Suppression of human colorectal cell growth by wild type p53. Science 1990;249:12-5.
67. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.
68. Levine A, Mornand J, Finlay C. The p53 tumour suppressor gene. Nature 1991;351:455-6.
69. Malkin D, Li F, Strong L, Fraumeni JF, Nelson LE, Kim DH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
70. Bartek J, Bartkova J, Vojtesen B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
71. Baker S, Preisinger A, Jessup J, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
72. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
73. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
74. Young J, Buttonshaw R, Butterworth L, et al. Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers. Oncogene 1994;9:1053-6.
75. Bosari S, Viale G, Bossi P, et al. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator of colorectal adenocarcinomas. JNCI 1994;86:681-7.
76. Finkelstein SD, Sayegh R, Bakker A, Swalsky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-32.
77. Pricolo VE, Finkelstein SD, Wu T-T, et al. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996;171:1-6.
78. Boughdady A, Kinsella A, Haboubi N, Schofield P. K-ras gene mutations in colorectal adenomas and carcinomas from familial adenomatous polyposis patients. Surg Oncol 1992;1:269-74.
79. McLellan A, Owen R, Stepniewska K, et al. High frequency of K-ras mutations in sporadic colorectal carcinomas. Gut 1993;34:392-6.
80. Vivona AA, Shpitz B, Medline A, et al. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 1993;14:1777-81.
81. Chaubert P, Benhattar J, Saraga E, Costa J. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol 1994;144:767-75.
82. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Cancer 1993;71:3827-38.
83. Finkelstein SD, Przygodski R, Pricolo V, et al. K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Arch Surg 1994;129:367-73.
84. Reinvikos Y, Tominaga O, Hammel P, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992;66:758-64.
85. McKenna W, Weiss M, Bakanauskas V, et al. The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 1990;18:849-59.
86. Niimi S, Nagakawa K, Yokota J, et al. Resistance to anticancer drugs in NII-13T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 1991;63:237-41.
87. Sidransky D, Tokino T, Hamilton S, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
88. Roth J. Modulation of oncogene and tumor-suppressor gene expression: a novel strategy for cancer prevention and treatment. Ann Surg Oncol 1994;1:79-86.
89. Coburn M, Pricolo V, DeLuca F, Bland K. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995;2:386-91.